LIVN
Bearish signalScored 2026-09-16 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
LivaNova PLC
- Nom
- LivaNova PLC
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $4.5B
- Employés
- 3,300
- PDG
- Vladimir A. Makatsaria
- Site web
- https://www.livanova.com
- Marché
- BSXCVRXEWHAEINSPMDT
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 7 450 titres (~591 840,34 $ US)
- Insiders
- Bianchi FrancescoStory Brooke
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$799,783
Avg sell (VWAP, 90d window) $78.99 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-10
- Last synced
-
2026-09-16 10:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-10 | Bianchi Francesco | Sell · S | 3,500 | $78.01 | $273,032 | Form 4 |
| 2026-09-04 | Story Brooke | Sell · S | 2,300 | $81.42 | $187,270 | Form 4 |
| 2026-08-31 | Bianchi Francesco | Sell · S | 1,650 | $79.72 | $131,538 | Form 4 |
| 2026-08-11 | Tezel Ahmet | Sell · S | 2,675 | $77.74 | $207,942 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-16 Drivers: fundamentals. Moteurs : fondamentaux.
LIVN presents a mixed profile: a moderate earnings catalyst supported by a Q2 2026 beat and raised outlook in Cardiopulmonary and Epilepsy segments provides near-term upside potential, but the weak fundamental trend…
The first sentence of the analysis written for LIVN on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.36 · operating margin 14%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.7% | 69.5% | 66.9% | 69.2% | 68.2% | |
| Ebit Margin | -12.4% | 12.1% | -1.9% | -2.6% | -7.2% | |
| Ebitda Margin | -9.3% | 16.2% | 3.3% | 3.0% | -0.6% | |
| Operating Profit Margin | 14.4% | 10.3% | -5.9% | -7.5% | -0.1% | |
| Pretax Profit Margin | -15.9% | 7.0% | -7.1% | -7.4% | -12.0% | |
| Continuous Operations Profit Margin | -17.5% | 5.0% | 1.5% | -8.4% | -13.1% | |
| Net Profit Margin | -17.5% | 5.0% | 1.5% | -8.4% | -13.1% | |
| Bottom Line Profit Margin | -17.5% | 5.0% | 1.5% | -8.4% | -13.1% | |
| Current Ratio | 1.363 | 2.875 | 2.950 | 2.980 | 0.974 | |
| Quick Ratio | 1.159 | 2.498 | 2.508 | 2.545 | 0.823 | |
| Solvency Ratio | -0.143 | 0.096 | 0.068 | -0.026 | -0.075 | |
| Cash Ratio | 0.787 | 1.094 | 0.796 | 0.720 | 0.298 | |
| Price To Earnings Ratio | -13.827 | 39.581 | 156.788 | -34.497 | -32.623 | |
| Price To Earnings Growth Ratio | 0.029 | 0.155 | -1.301 | 0.864 | 0.526 | |
| Forward Price To Earnings Growth Ratio | 0.029 | 0.155 | -1.301 | 0.864 | 0.526 | |
| Price To Earnings Diluted Ratio | -13.827 | 39.922 | 161.688 | -34.497 | -32.623 | |
| Price To Earnings Diluted Growth Ratio | 0.029 | 0.152 | -1.349 | 0.864 | 0.526 | |
| Price To Book Ratio | 2.794 | 1.903 | 2.183 | 2.461 | 3.419 | |
| Price To Sales Ratio | 2.416 | 2.004 | 2.418 | 2.908 | 4.276 | |
| Price To Free Cash Flow Ratio | 19.361 | 18.479 | 69.837 | 68.465 | 57.442 | |
| Price To Operating Cash Flow Ratio | 13.187 | 13.723 | 37.226 | 42.509 | 43.170 | |
| Debt To Assets Ratio | 0.182 | 0.270 | 0.264 | 0.253 | 0.130 | |
| Debt To Equity Ratio | 0.394 | 0.513 | 0.501 | 0.481 | 0.221 | |
| Debt To Capital Ratio | 0.283 | 0.339 | 0.334 | 0.325 | 0.181 | |
| Long Term Debt To Capital Ratio | 0.247 | 0.294 | 0.308 | 0.300 | 0.008 | |
| Financial Leverage Ratio | 2.172 | 1.898 | 1.902 | 1.900 | 1.700 | |
| Working Capital Turnover Ratio | 2.699 | 1.806 | 1.858 | 3.579 | 5.432 | |
| Operating Cash Flow Ratio | 0.315 | 0.467 | 0.224 | 0.235 | 0.147 | |
| Operating Cash Flow Sales Ratio | 0.183 | 0.146 | 0.065 | 0.068 | 0.099 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.681 | 0.743 | 0.533 | 0.621 | 0.752 | |
| Debt Service Coverage Ratio | -1.870 | 1.258 | 1.785 | 0.277 | -0.063 | |
| Interest Coverage Ratio | 4.046 | 2.046 | -1.164 | -1.591 | -0.016 | |
| Short Term Operating Cash Flow Coverage Ratio | 8.073 | 2.347 | 4.136 | 2.983 | 0.446 | |
| Operating Cash Flow Coverage Ratio | 0.537 | 0.270 | 0.117 | 0.120 | 0.358 | |
| Capital Expenditure Coverage Ratio | 3.136 | 3.886 | 2.142 | 2.638 | 4.025 | |
| Dividend Paid And Capex Coverage Ratio | 3.136 | 3.886 | 2.142 | 2.638 | 4.025 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -24.642 | 13.627 | 82.184 | 108.000 | -711.441 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.7% | ▼-1.8% | ▼-0.6% |
| Ebit Margin | -12.4% | ▼-24.4% | ▼-10.0% |
| Ebitda Margin | -9.3% | ▼-25.5% | ▼-11.8% |
| Operating Profit Margin | 14.4% | ▲4.1% | ▲12.1% |
| Pretax Profit Margin | -15.9% | ▼-22.9% | ▼-8.8% |
| Continuous Operations Profit Margin | -17.5% | ▼-22.5% | ▼-11.0% |
| Net Profit Margin | -17.5% | ▼-22.5% | ▼-11.0% |
| Bottom Line Profit Margin | -17.5% | ▼-22.5% | ▼-11.0% |
| Current Ratio | 1.363 | ▼-1.511 | ▼-0.865 |
| Quick Ratio | 1.159 | ▼-1.339 | ▼-0.747 |
| Solvency Ratio | -0.143 | ▼-0.239 | ▼-0.127 |
| Cash Ratio | 0.786 | ▼-0.307 | ▲0.048 |
| Price To Earnings Ratio | -13.827 | ▼-53.408 | ▼-36.911 |
| Price To Earnings Growth Ratio | 0.029 | ▼-0.127 | ▼-0.026 |
| Forward Price To Earnings Growth Ratio | 0.029 | ▼-0.127 | ▼-0.026 |
| Price To Earnings Diluted Ratio | -13.827 | ▼-53.749 | ▼-37.960 |
| Price To Earnings Diluted Growth Ratio | 0.029 | ▼-0.123 | ▼-0.016 |
| Price To Book Ratio | 2.795 | ▲0.892 | ▲0.242 |
| Price To Sales Ratio | 2.416 | ▲0.412 | ▼-0.388 |
| Price To Free Cash Flow Ratio | 19.361 | ▲0.882 | ▼-27.355 |
| Price To Operating Cash Flow Ratio | 13.187 | ▼-0.536 | ▼-16.776 |
| Debt To Assets Ratio | 0.182 | ▼-0.088 | ▼-0.038 |
| Debt To Equity Ratio | 0.394 | ▼-0.118 | ▼-0.028 |
| Debt To Capital Ratio | 0.283 | ▼-0.056 | ▼-0.009 |
| Long Term Debt To Capital Ratio | 0.247 | ▼-0.047 | ▲0.016 |
| Financial Leverage Ratio | 2.172 | ▲0.273 | ▲0.257 |
| Working Capital Turnover Ratio | 2.699 | ▲0.893 | ▼-0.376 |
| Operating Cash Flow Ratio | 0.315 | ▼-0.152 | ▲0.037 |
| Operating Cash Flow Sales Ratio | 0.183 | ▲0.037 | ▲0.071 |
| Free Cash Flow Operating Cash Flow Ratio | 0.681 | ▼-0.062 | ▲0.015 |
| Debt Service Coverage Ratio | -1.870 | ▼-3.128 | ▼-2.148 |
| Interest Coverage Ratio | 4.046 | ▲2.000 | ▲3.381 |
| Short Term Operating Cash Flow Coverage Ratio | 8.073 | ▲5.726 | ▲4.476 |
| Operating Cash Flow Coverage Ratio | 0.537 | ▲0.267 | ▲0.257 |
| Capital Expenditure Coverage Ratio | 3.136 | ▼-0.750 | ▼-0.029 |
| Dividend Paid And Capex Coverage Ratio | 3.136 | ▼-0.750 | ▼-0.029 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -24.642 | ▼-38.269 | ▲81.813 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.35B | $2.51B | $2.79B | $2.97B | $4.43B | |
| Enterprise value | $3.19B | $2.76B | $3.16B | $3.34B | $4.51B | |
| EV / Sales | 2.30x | 2.20x | 2.74x | 3.27x | 4.35x | |
| EV / Op. cash flow | 12.55x | 15.08x | 42.22x | 47.75x | 43.94x | |
| EV / Free cash flow | 18.42x | 20.30x | 79.20x | 76.90x | 58.46x | |
| EV / EBITDA | -24.64x | 13.63x | 82.18x | 108.00x | -711.44x | |
| Net debt / EBITDA | 1.25x | 1.22x | 9.72x | 11.85x | -12.43x | |
| Current ratio | 1.36x | 2.88x | 2.95x | 2.98x | 0.97x | |
| Income quality | -1.05x | 2.90x | 4.27x | -0.81x | -0.76x | |
| Graham number | — | $25 | $13 | — | — | |
| Graham net-net | -$10 | -$10 | -$12 | -$12 | -$9 | |
| Tax burden | 109.8% | 71.6% | -21.6% | 114.7% | 109.0% | |
| Interest burden | 128.7% | 58.3% | 363.5% | 279.6% | 167.7% | |
| Working capital | $293.5M | $735.1M | $653.2M | $588.7M | -$17.8M | |
| Invested capital | $1.61B | $1.94B | $1.90B | $1.91B | $1.47B | |
| Return on assets | -9.3% | 2.5% | 0.7% | -3.8% | -6.2% | |
| Operating ROA | 7.8% | 5.2% | -2.9% | -3.4% | -0.0% | |
| Return on tangible assets | -15.3% | 4.2% | 1.3% | -7.5% | -15.1% | |
| Return on equity | -20.2% | 4.8% | 1.4% | -7.1% | -10.5% | |
| Return on invested capital | 10.9% | 4.2% | 0.7% | -3.8% | -0.0% | |
| Return on capital employed | 11.1% | 6.1% | -3.3% | -3.8% | -0.1% | |
| Earnings yield | -7.2% | 2.5% | 0.6% | -2.9% | -3.1% | |
| Free cash flow yield | 5.2% | 5.4% | 1.4% | 1.5% | 1.7% | |
| Capex / Op. cash flow | 31.9% | 25.7% | 46.7% | 37.9% | 24.8% | |
| Capex / Depreciation | 193.1% | 92.1% | 57.5% | 45.8% | 37.5% | |
| Capex / Sales | 5.8% | 3.8% | 3.0% | 2.6% | 2.5% | |
| SG&A / Sales | 39.5% | 42.0% | 44.9% | 45.9% | 45.6% | |
| R&D / Sales | 13.4% | 14.6% | 16.8% | 15.2% | 17.7% | |
| Stock comp / Sales | 2.6% | 2.7% | 3.2% | 4.4% | 3.9% | |
| Intangibles / Total assets | 39.2% | 39.4% | 43.0% | 49.6% | 59.0% | |
| Days sales outstanding | 57d | 65d | 68d | 77d | 79d | |
| Days payables outstanding | 79d | 67d | 77d | 86d | 75d | |
| Operating cycle | 191d | 206d | 209d | 227d | 196d | |
| Cash conversion cycle | 112d | 139d | 132d | 141d | 121d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-14 LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 LivaNova Director Sells 1,650 Shares for $131,500 The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director''s equity stake held directly before the filing.
- 2026-08-15 LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DE Bank of America Corp DE cut its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 30.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 533,017 shares of the company''s stock after selling 235,233 shares during the quarter. Bank of America Corp
- 2026-08-10 Dynatronics (NASDAQ:DYNT) vs. LivaNova (NASDAQ:LIVN) Critical Review LivaNova (NASDAQ: LIVN - Get Free Report) and Dynatronics (NASDAQ: DYNT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Risk and Volatility LivaNova has a beta of 0.86, indicating
- 2026-08-06 LivaNova Q2 Earnings & Revenues Beat Estimates, ''26 Outlook Raised LIVN''s Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
- 2026-08-05 LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
- 2026-08-05 LivaNova Q2 Earnings Call Highlights LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.
- 2026-08-05 LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-05 LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run? LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company''s fundamentals for clues.
- 2026-08-05 LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago.